PRIMARY THERAPY OF ADVANCED OVARIAN CANCER

1968 ◽  
Vol 11 (2) ◽  
pp. 388
Author(s):  
&NA;
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Primary Therapy

scholarly journals Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up

2011 ◽  
Vol 22 ◽  
pp. viii40-viii44 ◽  
Author(s):  
S. Pignata ◽  
L. Cannella ◽  
D. Leopardo ◽  
G.S. Bruni ◽  
G. Facchini ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Primary Therapy

scholarly journals Is it possible to improve primary therapy of advanced ovarian cancer?

2020 ◽  
pp. 128-135
Author(s):  
S. V. Khokhlova
Keyword(s):  
Ovarian Cancer ◽  
Life Expectancy ◽  
Brca1 Mutation ◽  
Advanced Ovarian Cancer ◽  
Subsequent Treatment ◽  
Low Grade ◽  
Primary Therapy ◽  
Average Life Expectancy ◽  
Ovarian Adenocarcinoma ◽  
Specific Patient

In 2011, a standard approach to the treatment of primary ovarian cancer (OC) included a cytoreductive surgery, which could be performed after 2–3 cycles of neoadjuvant chemotherapy, and chemotherapy consisting of platinum and taxanes. Such approach was provided for all patients, regardless of tumour histology and any molecular biological and genetic factors. The most complete picture of management and therapy of patients can be made using the treatment of a specific patient as an example. After application to the N.N. Blokhin National Medical Research Center of Oncology in 2011, the patient with OC received standard primary therapy and subsequent treatment of the recurrent disease, which was accompanied by various types of adverse events resulting in the poor quality of life for the patient. The data that some patients with OC have a BRCA1/2 mutation that is significant for prognosis and treatment came to hand later and, unfortunately, the awareness of a significant germinal BRCA1 mutation was of no use to the woman any longer. The life expectancy of this patient was 47 months. This is the average life expectancy for patients with stage IIIC OC. Major changes have been brought in the primary therapy of OC. If a diagnosis of low-grade IIIC ovarian adenocarcinoma was established in this patient today, needless to say that the BRCA1 mutation would be identified during the first-line chemotherapy, and in case of full or partial treatment effect, we would prescribe olaparib as maintenance therapy to the patient. Considering the fact that the median progression-free survival has not yet been achieved in the patients of SOLO-1 study, who received olaparib therapy, and is only approaching 54 months, it can be assumed that even the first relapse could not have developed in this patient.

Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.

1998 ◽  
Vol 16 (5) ◽  
pp. 1849-1851 ◽  
Author(s):  
M Markman ◽  
P G Rose ◽  
E Jones ◽  
I R Horowitz ◽  
A Kennedy ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Treatment Strategy ◽  
Randomized Study ◽  
Advanced Ovarian Cancer ◽  
Primary Carcinoma ◽  
Primary Therapy ◽  
Prolonged Infusion ◽  
Fallopian Tube Cancer ◽  
Improve Outcome

PURPOSE To test the hypothesis that prolonged infusion of paclitaxel (96 hours) might overcome resistance to shorter infusion schedules (3 or 24 hours) in ovarian cancer. PATIENTS AND METHODS A total of 30 patients with advanced ovarian cancer (24 patients), primary carcinoma of the peritoneum (four patients), or fallopian tube cancer (two patients) who previously had received paclitaxel administered on either a 3-hour or 24-hour schedule were treated with the agent delivered as a 96-hour infusion (30 to 35 mg/m2/d x 4 days) on an every 3-week program. RESULTS Although the regimen generally was well tolerated, no objective responses were observed. CONCLUSION In patients with ovarian cancer who have shown resistance to shorter paclitaxel infusion schedules, ninety-six hour infusional paclitaxel is an inactive treatment strategy. This makes it less likely that protracted infusion of paclitaxel will improve outcome when used as part of primary therapy of ovarian cancer. An ongoing randomized study will answer that question.

scholarly journals Continued chemotherapy after complete response to primary therapy among women with advanced ovarian cancer

Cancer ◽  
2010 ◽  
Vol 116 (22) ◽  
pp. 5251-5260 ◽  
Author(s):  
Lisa M. Hess ◽  
Nan Rong ◽  
Patrick O. Monahan ◽  
Paridha Gupta ◽  
Champ Thomaskutty ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Complete Response ◽  
Primary Therapy

scholarly journals The Impact of Body Weight on Ovarian Cancer Outcomes

2011 ◽  
Vol 21 (9) ◽  
pp. 1601-1605 ◽  
Author(s):  
Floor J. Backes ◽  
Christa I. Nagel ◽  
Elizabeth Bussewitz ◽  
Jessica Donner ◽  
Erinn Hade ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Confidence Interval ◽  
Cancer Biology ◽  
Advanced Ovarian Cancer ◽  
Normal Weight ◽  
Primary Therapy ◽  
Cancer Outcomes ◽  
Poor Prognostic Factor ◽  
Increased Risk ◽  
The Impact

BackgroundObesity is a known risk factor and poor prognostic factor for many comorbidities including cancer. However, the influence of body mass index (BMI) on ovarian cancer outcomes is inconclusive. Therefore, the objective of this study was to evaluate the impact of BMI and weight changes on survival in patients with advanced ovarian cancer after primary treatment.MethodsAll patients with a diagnosis of advanced epithelial ovarian cancer from January 2000 to December 2007 undergoing primary cytoreductive surgery and adjuvant chemotherapy were identified. Patients were divided into 3 categories: underweight/normal weight (BMI, <25 kg/m2), overweight (BMI, 25–30 kg/m2), and obese (BMI, >30 kg/m2). Adjusted hazard ratios for progression-free survival (PFS) and overall survival (OS) were calculated via Cox proportional hazards models.ResultsOne hundred ninety-eight patients met the inclusion criteria. For all patients, the mean BMI was 26 kg/m2 (range, 16.4–49.1 kg/m2), with 43% of patients being classified as normal weight, 29% overweight, and 28% as obese. Median 5-year OS was 48.2 months (95% confidence interval, 16.4–49.1 months), and no differences in OS were noted between BMI groups. Unadjusted median PFS for patients with normal weight was 13.7 months, compared with 15.5 and 17.9 months for the overweight and obese groups. Adjusted analysis of BMI over time indicates a trend of increased risk for patients who gain weight in the 6 months after primary therapy on disease progression (hazard ratio, 1.68; 95% confidence interval, 0.87–3.26).ConclusionsAfter adjustment for confounders, such as stage, grade, histology, age, and debulking status, data suggest a trend toward a shorter PFS in patients with a normal BMI. However, OS was not significantly related to BMI, and weight change in the 6 months after completion of treatment had no effect on PFS or OS. Further research should be directed at elucidating relationships between weight and cancer biology.

Sign in / Sign up

Export Citation Format

Share Document